Skip to main content

Table 1 Baseline patient, donor and disease characteristics at diagnosis

From: Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Clinical parameter MSD (n = 1891) Haplo (n = 413) p
Follow-up duration in m, median (range) 24.88 (12.13;46.05) 25.37 (13.21;42.56) 0.92
Age at transplant in years, median (range) 37.7 (18–76.1) [27–49.5] 37.1 (18.1–75) [25.7–51] 0.58
Year of transplant 2015 (2012–2018) 2016 (2012–2018) < 0.0001
Patient gender, n (%)    
Male 1129 (59.8%) 268 (64.9%) 0.055
Female 759 (40.2%) 145 (35.1%)  
Diagnosis    
Ph-neg B ALL 616 (32.6%) 148 (35.8%) 0.44
Ph-pos B ALL 725 (38.3%) 151 (36.6%)  
T-ALL 550 (29.1%) 114 (27.6%)  
Patient CMV status    
Patient CMV negative, n (%) 521 (28.1%) 90 (22%) 0.01
Patient CMV positive, n (%) 1335 (71.9%) 319 (78%)  
Donor CMV status    
Donor CMV negative, n (%) 599 (33%) 110 (27.1%) 0.021
Donor CMV positive, n (%) 1215 (67%) 296 (72.9%)  
Status at transplant    
CR1 1575 (83.3%) 275 (66.6%) < 0.0001
CR2 316 (16.7%) 138 (33.4%)  
KPS at transplant, n (%)    
< 90 397 (22.4%) 100 (25%) 0.27
≥ 90 1373 (77.6%) 300 (75%)  
Missing 121 13  
Donor age, y median (range) 38.5 (0.1–74) [27.5–50.5] 38.8 (7.8–74.3) [27.1–49.3] 0.79
Donor gender    
Male donor 1033 (54.9%) 242 (58.6%) 0.17
Female donor 848 (45.1%) 171 (41.4%)  
Donor-recipient gender matching, n (%)    
Female–male 474 (25.2%) 110 (26.6%) 0.54
Other 1408 (74.8%) 303 (73.4%)  
MRD at transplant    
Negative 681 (67.4%) 162 (65.3%) 0.54
Positive 330 (32.6%) 86 (34.7%)  
Missing 880 165  
  1. KPS, Karnofsky performance status;TBI, total body irradiation; CMV, cytomegalovirus; MRD, measurable residual disease